20 South Sarah Street St. Louis, MO 63108 314-615-6355 info@biogenerator.org
Eric G

Eric Gulve, Ph.D.

President

Eric Gulve, Ph.D. joined BioGenerator in 2007 following a 14 year career in the pharmaceutical industry. In 2009 he assumed overall leadership of BioGenerator. His responsibilities have expanded to include overall strategic direction, expansion of programs and services, oversight of the organizational budget, community outreach, regional collaborations, and service on the Board of Directors of several BioGenerator portfolio companies.

Prior to joining BioGenerator, Eric spent 14 years in the pharmaceutical industry focused on drug discovery research. From 2003 – 2007 he held various roles in local and global leadership teams in Cardiovascular research at Pfizer, and led laboratories working in the areas of thrombosis, hypertension, and metabolic disease. From 2000 – 2003, Eric was Associate Director of the Cardiovascular & Metabolic Diseases research group at Pharmacia Corporation, prior to Pharmacia’s acquisition by Pfizer. From 1994 – 2000 he directed laboratory groups and served on leadership teams within G.D. Searle’s Cardiovascular drug discovery research group, where he established the company’s first diabetes research program. In addition to laboratory oversight and roles on therapeutic area discovery research leadership teams, Eric held other leadership roles, e.g. on drug discovery teams and new drug target identification/validation teams. In all three companies he held various roles on cardiovascular and metabolic disease therapeutic area in-licensing teams. Eric has worked collaboratively across different research lines, therapeutics areas, business units, and geographic sites. Over the course of his career he has supervised or mentored Ph.D., M.S. and B.A. scientists working inside and outside of his laboratories.

Eric received an A.B. in Chemistry from Occidental College (Los Angeles) and a Ph.D. in Physiology from Harvard University. He served as post-doctoral fellow and research faculty at Washington University School of Medicine, where his research focused on skeletal muscle metabolism and the molecular mechanisms which contribute to the beneficial effects of exercise in diabetes and other states characterized by defective glucose metabolism. He has worked directly or overseen the work of direct reports in a number of different fields including skeletal muscle carbohydrate and protein metabolism, diabetes, thrombosis, and hypertension. Eric has published over 40 peer-reviewed articles and has contributed to several book chapters and review articles. He continues to lecture periodically on the subjects of skeletal muscle metabolism, diabetes, and muscle protein turnover.

Getting Started

Entrepreneurs Investors